Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
Resignation of Peter Justin Klein as Director
On September 14, 2021, Peter Justin Klein resigned from the board of directors
(the "Board") of PhaseBio Pharmaceuticals, Inc. (the "Company"). Dr. Klein was a
Class I director whose term was to expire at the Company's 2022 annual meeting
of stockholders (the "2022 Annual Meeting") and was a member of the Compensation
Committee. His decision to resign was not the result of any disagreement with
the Company relating to its operations, policies or practices.
Appointment of William Humphries as Director
On September 14, 2021, the Board appointed William Humphries to serve as a
director of the Company, effective upon the resignation of Dr. Klein. Mr.
Humphries will serve as a Class I director whose term will expire at the 2022
Annual Meeting, at which time he will stand for election by the Company's
stockholders. Mr. Humphries was also appointed as a member of the Compensation
Committee.
There is no arrangement or understanding between Mr. Humphries and any other
person pursuant to which he was selected as a director of the Company, and there
is no family relationship between Mr. Humphries and any of the Company's other
directors or executive officers. The Company is not aware of any transaction
involving Mr. Humphries requiring disclosure under Item 404(a) of Regulation
S-K.
Mr. Humphries, age 55, has served as Chief Executive Officer of Isosceles
Pharmaceuticals Inc., a biotechnology company, since May 2021. From August 2018
until December 2020, Mr. Humphries served as President and Group Company
Chairman, Ortho Dermatologics of Bausch Health Companies Inc., where he
previously served as Executive Vice President, Company Group Chairman,
Dermatology from January 2017 to August 2018. From 2012 to December 2016, he
served as President and Chief Executive Officer of the North American business
of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare
company. From 2004 to 2012, he served in a number of leadership positions with
Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as
its Chief Commercial Officer and then as its President beginning in 2008.
Stiefel was acquired by GlaxoSmithKline in 2009, after which Mr. Humphries
served as the President of Dermatology for Stiefel from 2009 until 2012. Prior
to Stiefel, Mr. Humphries served in executive roles in sales and marketing,
business development, and international marketing for Allergan, Inc., concluding
as vice president of its U.S. skincare business. Mr. Humphries has served on the
boards of directors of STRATA Skin Sciences, Inc. since April 2021, Aclaris
Therapeutics, Inc. since 2016, and Clearside Biomedical, Inc. since 2012. He
received a Bachelor of Arts from Bucknell University and a Master of Business
Administration from Pepperdine University. The Board believes that Mr. Humphries
is qualified to serve as a director because of his extensive experience as an
executive and board member with life science companies, including with respect
to sales and marketing.
In accordance with the Company's Non-Employee Director Compensation Policy, as
amended, upon commencement of his service as a director on September 14, 2021,
Mr. Humphries was granted an initial option grant (the "Initial Grant") under
the Company's 2018 Equity Incentive Plan (the "Plan") to purchase 28,000 shares
of the Company's common stock, which will vest in equal monthly installments
over a three-year period such that the option is fully vested on the third
anniversary of the date of grant, subject to Mr. Humphries' continuous service
through such vesting dates. At each annual meeting of stockholders following
which Mr. Humphries will continue service as a director, Mr. Humphries will also
be entitled to receive an additional option grant to purchase 14,000 shares of
the Company's common stock (the "Annual Grant"), which will vest upon the
earlier of the one-year anniversary of the date of grant and the date of
Company's next annual meeting of stockholders, in any case subject to Mr.
Humphries' continuous service through such vesting dates. Additionally, Mr.
Humphries will be entitled to receive a $40,000 annual retainer, payable
quarterly in arrears, for his service on the Board, and a $6,000 annual
retainer, payable quarterly in arrears, for his service on the Compensation
Committee. Mr. Humphries has also entered into the Company's standard form of
indemnification agreement.
Composition of Board Committees
As a result of Mr. Humphries' appointment and Dr. Klein's resignation from the
Board, the composition of each of the Board's committees is as follows,
effective immediately:
Audit Committee
•Caroline Loewy (Chair)
•Alex Sapir
--------------------------------------------------------------------------------
•Richard van den Broek
Compensation Committee
•Nancy Hutson (Chair)
•Edmund Harrigan
•William Humphries
•Clay Thorp
Nominating and Corporate Governance Committee
•Clay Thorp (Chair)
•Nancy Hutson
•Richard van den Broek
Item 7.01. Regulation FD Disclosure.
On September 15, 2021, the Company issued a press release announcing the
appointment of Mr. Humphries to the Board. A copy of the press release is
furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before
or after the date hereof, except as expressly set forth by specific reference in
such filing to this item of this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
Press Release, dated September 15, 2021, entitled "PhaseBio Appoints
99.1 William D. Humphries to Board of Directors".
104 Cover page interactive data file (formatted as Inline XBRL).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses